Navigation Links
BioCrossroads Invests in Innovative Biotech Targeting Challenging Diseases
Date:12/23/2010

INDIANAPOLIS, Dec. 23, 2010 /PRNewswire/ -- BioCrossroads' Indiana Seed Fund has announced its eleventh investment, committing $250,000 to biotech start-up Aarden Pharmaceuticals.  Based in Indianapolis but drawing key parts of its veteran entrepreneurial team from San Diego, Aarden is developing novel technologies to attack difficult-to-treat diseases through focus on specific intracellular disease targets. The BioCrossroads investment will support the company to advance its lead program, a tuberculosis (TB) treatment, through the pre-clinical development stage. 

Aarden's scientific platform comes through the work of Dr. Zhong-Yin Zhang, Robert A. Harris Professor and Chairman of Biochemistry and Molecular Biology at Indiana University School of Medicine, and an internationally recognized expert in the field of protein tyrosine phosphatases (PTPs), a large family of signaling enzymes that regulate a wide array of essential cellular processes.  Dr. Zhang's work is based on novel chemistry that allows drugs to work more effectively in finding their targets.

"Aarden's research was born in Dr. Zhang's laboratory, which was funded through Lilly Endowment's historic Indiana Genomics Initiative (INGEN) grant to the Indiana University School of Medicine several years ago," said David Johnson, president and CEO of BioCrossroads.  "The goal of INGEN was to make Indiana a destination point for 21st century biotechnology discovery and, in so doing, bring more translational research to life for better human health.  Aarden's promising science, pre-eminent research and outstanding leadership team illustrate very well the full promise of the grant."

The second leading cause of death in the world, approximately 2 million people die from tuberculosis each year.   Current treatments are insufficient.  Often, existing antibiotics are not fully effective, particularly against multi-drug resistant TB under a regimen that demands arduous treatments for up to nine months.  Aarden's drug has the potential to address current challenges – offering a shorter treatment duration and a stronger, more efficacious treatment.

Along with its TB therapeutic platform, Aarden is also making progress in research efforts in cancer (e.g. leukemia) and autoimmune diseases (e.g. rheumatoid arthritis and lupus).  The company's cancer and autoimmune programs are currently in pre-clinical testing.

"BioCrossroads' continuing support has value even beyond this important financial commitment.  Certainly, this investment from the BioCrossroads Seed Fund will help us accelerate the progress of our TB program," said Aarden CEO Gary Noonan.  "It's a testament to our science and team that we are now part of the group of high caliber start ups that BioCrossroads has funded."

About BioCrossroads

BioCrossroads (www.biocrossroads.com) is Indiana's initiative to grow, advance and invest in the life sciences, a publicprivate collaboration that supports the region's existing research and corporate strengths while encouraging new business development.  BioCrossroads provides money and support to life sciences businesses, launches new life sciences enterprises (Indiana Health Information Exchange, Fairbanks Institute for Healthy Communities, BioCrossroadsLINX, and Datalys Center), expands collaboration and partnerships among Indiana's life science institutions, promotes science education and markets Indiana's life sciences industry.

About the Indiana Seed Fund I

The $6 million, returndriven Indiana Seed Fund was launched in June 2005 and is managed by BioCrossroads with funding from BioCrossroads, the Indiana Finance Authority and the Indiana Economic Development Corporation.  The Seed Fund provides working capital in the range of $50,000$500,000 to promising Indiana life sciences companies at the preliminary stages of operation.

About Aarden

Aarden (www.aardenpharma.com) is a small molecule drug discovery and development company.  The company's novel technology from the labs of the Indiana University School of Medicine is a chemistry breakthrough that will enable it to make drugs against a previously undruggable set of intracellular phosphatase (PTP) disease targets. Aarden's first programs are focused on infectious disease, cancer, metabolic and autoimmune conditions.  


'/>"/>
SOURCE BioCrossroads
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. BioCrossroads Indiana Seed Fund Invests in Vaccine Biotech Company
2. BioCrossroads Invests in Indianapolis Biotech Company Developing Treatments for Alzheimers Disease
3. Orthopedics Entrepreneur Named BioCrossroads Watanabe Life Sciences Champion of the Year
4. Carilion Clinic Invests in Sight Saving Technology to Improve Patient Care: Carilion Clinic Teams Up with Retasure
5. Lockheed Martin Invests in Smart Grid Research and Development at Penn State University
6. Burrill & Company Invests in Taiwan Liposome Company
7. University of Lodz Invests in the Unique Cellaxess(R)HT System for Research on Multidrug Resistance Genes in Cancer
8. The Pittsburgh Life Sciences Greenhouse Invests $725K in Portfolio Companies
9. Syngenta Ventures Invests in U.S. Biotech Company Metabolon
10. BR Ventures Invests in Semprae Laboratories
11. Federal grant invests in nanostructured super materials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... CALGARY , Dec. 7, 2016 /PRNewswire/ - Zenith Capital Corp. ... update that will be presented at the Company,s Annual and ... Meeting of Shareholders will take place on Thursday, December 15, ... Ross Glenn Hall (Room EC1040), 4825 Mount Royal Gate ... am (MST). A notice of meeting and management information circular, ...
(Date:12/7/2016)... the association for the California life ... st Century Cures legislation in Congress. The bill passed ... and in the Senate on December 7 by a 94-5 ... , president & CEO of Biocom: "Today, Congress ... patients around the world. The measure culminates three years of ...
(Date:12/7/2016)... -- Vyriad Inc. announced today the appointment of Alvin ... "We are delighted to welcome Al to ... our oncolytic viruses as the next generation of precision ... MD, PhD, CEO of Vyriad. "Al and his wife, ... for making a difference for cancer patients—their philanthropy has ...
(Date:12/7/2016)...  Muse bio, a privately-held company leading the development ... Kevin Ness has been appointed Chief Executive ... Kevin succeeds Muse bio,s founding CEO ... Officer as well as remains Slade Professor, Chemical and ... at the RAS Energy Institute at the University of ...
Breaking Biology Technology:
(Date:12/8/2016)... , Dec. 8, 2016  Singulex, Inc., the ... Counting technology, entered into a license and supply agreement ... science. The agreement provides Singulex access to Thermo Scientific ... Europe is used to diagnose systemic bacterial ... States to aid in assessing the risk ...
(Date:12/7/2016)... Avanade is helping Williams Martini Racing, one of ... biometric data in order to critically analyse every aspect ... against their rivals after their impressive, record-breaking pit stop ... with Williams during the 2016 season to capture and ... rate, temperature and peak acceleration) for key members of ...
(Date:12/6/2016)... Valencell , the leading innovator in performance biometric ... consecutive year of triple digit growth for its PerformTek ... 360 percent increase in companies who have acquired Valencell ... sales of its wrist and ear Benchmark™ sensor systems, ... hearables for fitness and healthcare applications. ...
Breaking Biology News(10 mins):